---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-11-20T06:58:57.114812'
end_time: '2025-11-20T07:04:34.250936'
duration_seconds: 337.14
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 78
---

## Question

Here is a pathway that describes how a drug might affect a disease:

**Pathway:** SmallMolecule: Sildenafil | causes | Disease: cerebrovascular disorder | treats_or_applied_or_studied_to_treat | SmallMolecule: Mannitol | contributes_to | Disease: Alzheimer disease

**Drug:** Sildenafil
**Disease:** Alzheimer disease

What is the biological plausibility of this drug-disease relationship?

Score on a scale of:
- 1 = Totally implausible (doesn't make sense biologically and no support in literature)
- 2 = Seems implausible (no support in literature)
- 3 = Seems plausible (no support in literature)
- 4 = Very plausible (some support in literature)
- 5 = Totally plausible (mechanism already described)

Consider:
- Has this exact mechanism been described in the literature?
- Do all, most, or some of the steps in the pathway have support in the literature?
- Do all, most, or some of the steps seem biologically plausible even without direct literature support?


## Output

# Introduction   
Sildenafil – a phosphodiesterase-5 (PDE5) inhibitor best known as Viagra – has been hypothesized as a potential therapy for Alzheimer’s disease (AD) based on vascular and biochemical mechanisms. The pathway proposed involves **Sildenafil** affecting **cerebrovascular function**, alongside the use of **mannitol** (an osmotic agent) to influence the brain, ultimately impacting **Alzheimer’s disease** pathology. To assess the **biological plausibility** of this drug-disease relationship, we examine the key mechanistic concepts, recent research findings (especially 2023–2024), current applications or studies, expert opinions, and relevant data. We will then assign a plausibility score from 1 (totally implausible) to 5 (mechanism well-described and supported), with thorough justification.

## Key Concepts and Mechanistic Rationale   
**PDE5 and cGMP in the Brain:** Alzheimer’s disease involves multiple pathological processes, including protein aggregates (amyloid-β plaques and tau tangles) and neuroinflammation, but vascular dysfunction is also a recognized factor ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should)). Notably, AD brains often show reduced nitric oxide (NO) and cyclic GMP signaling, partly due to overactive PDE5 enzymes that break down cGMP ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,1)). Sildenafil inhibits PDE5, thereby **raising cGMP levels** and restoring NO/cGMP signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,1)). This biochemical effect can have several downstream benefits. For instance, elevated cGMP activates protein kinase G (PKG), which in turn can phosphorylate CREB, activating pathways like **PGC-1α** (a regulator of metabolism) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term)). Through these pathways, **researchers propose that sildenafil may reduce β-secretase 1 (BACE1) expression and thus lower amyloid-β (Aβ) production, boost antioxidant defenses, and improve mitochondrial function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term))**. This indicates a plausible mechanism by which sildenafil could directly counter AD’s hallmark amyloid pathology at the molecular level.

**Cerebrovascular Effects:** In addition to biochemical effects, sildenafil’s vasodilatory action may improve brain perfusion and vascular health. AD patients often suffer cerebral hypoperfusion (reduced blood flow) and blood-brain barrier (BBB) dysfunction, which can exacerbate neurodegeneration ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should)). By relaxing blood vessels, PDE5 inhibitors can enhance cerebral blood flow or at least cerebrovascular reactivity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions)). Indeed, a systematic review found **PDE5 inhibitors improve cerebrovascular reactivity (the blood vessels’ response to stimuli) in certain conditions** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions)). In practical terms, sildenafil is being studied in cerebrovascular disorders – for example, trials have examined its effect on cerebral blood flow in stroke or small-vessel disease patients ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26940913/#:~:text=Cite%20Display%20options%20,neurologic%20function%20in%20experimental%20subarachnoid)). These studies suggest sildenafil can be administered safely without major adverse cerebrovascular effects, and in some cases it may increase regional perfusion or vasodilatory reserve. Improved brain perfusion and oxygenation could help cognitive function and potentially slow vascular contributions to dementia. Furthermore, **sildenafil’s neuroprotective effects under low-oxygen conditions have been noted in preclinical studies (e.g. it can suppress neuron apoptosis in hypoxic environments and promote neurogenesis) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil))**, which is highly relevant given the chronic cerebral hypoperfusion in AD. Thus, the **vasculature-related step in the pathway is biologically plausible**: enhancing NO/cGMP signaling with sildenafil can **ameliorate cerebrovascular dysfunction**, potentially benefiting brain metabolism and waste clearance.

**Mannitol and Blood-Brain Barrier (BBB):** Mannitol is a sugar alcohol that plays a very different but complementary role in the pathway. Medically, **mannitol is used as an osmotic diuretic to reduce intracranial pressure in acute brain injuries or stroke, and it is known to transiently open the BBB** by shrinking endothelial cells ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs)). Clinicians have leveraged intra-arterial mannitol infusions during neurosurgery or chemotherapy to increase drug delivery to the brain ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs)). In the context of neurodegenerative disease, this BBB-opening property is intriguing – a more permeable BBB might help clear toxic protein build-up or allow therapeutic molecules to reach the brain. While direct clinical trials in Alzheimer’s patients are lacking, researchers have explored mannitol in models of neurodegeneration. Notably, in a Parkinson’s disease model, **mannitol was found to reduce the aggregation of toxic proteins (α-synuclein) in the brain** ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Sagol%20School%20of%20Neuroscience%20researchers,the%20Lord%20Alliance%20Family%20Trust)), suggesting it can interfere with or flush out protein aggregates. By analogy, some scientists have speculated that mannitol or related agents might help disrupt amyloid aggregates or enhance Aβ clearance in AD, especially if combined with other therapies. At minimum, **mannitol’s ability to modulate the brain’s physical environment (fluid dynamics and barrier permeability) is well-documented**, and this lends plausibility to the idea that mannitol could contribute to treating neurological disorders. In our pathway, the link “mannitol contributes to Alzheimer’s disease” would refer to a *potential therapeutic contribution* – for example, using mannitol to improve drug delivery or reduce cerebral edema in AD. Although this exact step is more speculative than proven, it rests on established principles of neuropharmacology and is under active investigation in related contexts.

**Integrated Mechanism:** Combining these steps, the putative scenario is that sildenafil improves cerebral blood flow and neuron survival (addressing vascular and signaling deficits in AD), and this could synergize with methods like mannitol-induced BBB modulation to further aid the brain. Improved blood flow and a more permeable BBB might facilitate clearance of Aβ or distribution of therapeutic compounds. In theory, **better perfusion plus transient BBB opening could reduce neuropathology**: for instance, enhanced vascular clearance (sometimes called the glymphatic or interstitial fluid drainage pathway) might remove Aβ deposits more efficiently ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil)). While the *exact combined pathway* of “sildenafil causing a cerebrovascular change that mannitol then leverages to treat AD” has not been explicitly demonstrated in literature as a single chain, **each component of the chain is grounded in biological reality**. Sildenafil’s effects on brain vasculature and cellular signaling are documented, and mannitol’s effects on the BBB and cranial pressure are known; both could logically contribute to combating AD pathology. Overall, the mechanism linking this drug to the disease is **credible and multi-faceted**, involving vascular improvement, second-messenger signaling, and possibly enhanced protein clearance.

## Recent Developments (2023–2024 Research)   
In the last few years, interest in repurposing sildenafil for Alzheimer’s has grown, yielding both encouraging data and some debate. A high-profile study led by researchers at Cleveland Clinic in 2021 initially drew attention to sildenafil. They used computational network analysis to identify sildenafil as a promising AD drug candidate, then examined health insurance databases for real-world outcomes ([newsroom.clevelandclinic.org](https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=study%20builds%20upon%20the%20researchers%E2%80%99,prevent%20and%20treat%20Alzheimer%E2%80%99s%20disease)). **In a retrospective analysis of over 7 million people, sildenafil users had a significantly lower incidence of Alzheimer’s disease**. The NIH reported in late 2021 that people who took sildenafil were **69% less likely to develop AD over a 6-year follow-up** compared to non-users, even after adjusting for confounders ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age)). This large-scale association, published in the journal *Nature Aging*, made headlines as evidence that Viagra might protect brain health. Importantly, the same study provided a mechanistic clue: **in lab experiments on neurons derived from AD patients, sildenafil enhanced neurite growth and reduced tau protein hyperphosphorylation** – tau tangles are a hallmark of AD, so this indicated a direct neuroprotective effect at the cellular level ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD)).

Building on those findings, **research from 2023-2024 has sought to confirm and extend the sildenafil-AD link**. In early 2024, a Cleveland Clinic-led team (Feixiong Cheng et al.) reported new results in the *Journal of Alzheimer’s Disease*. They analyzed millions of de-identified patient records from two independent databases and again observed a strong association: **sildenafil use was linked to a 30%–54% reduced prevalence of Alzheimer’s diagnoses** compared to matched controls (or compared to users of another drug) ([newsroom.clevelandclinic.org](https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=In%20the%20new%20study%2C%20Dr,not%20after%20adjusting%20various%20possible)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to)). This study strengthened the evidence by using two cohorts and careful adjustment; one database showed a 54% lower relative prevalence, the other ~30% lower, among sildenafil users ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to)). The researchers also performed *in vitro* and *in vivo* experiments: for instance, **exposing patient-derived neurons to sildenafil reduced tau phosphorylation (at key AD-related sites pTau-181 and pTau-205) in a dose-dependent manner ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=95,derived))**. There was also a validation in an animal model (APOE4 gene knock-in AD mice) that supported the drug’s effect conceptually ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=exposure%20was%20associated%20with%20significantly,population%2C%20and%20in%20the%20treated)). These 2024 findings were widely discussed, as they provide a **convergence of epidemiological and experimental support** for sildenafil’s potential benefits in AD.

Around the same time (early 2024), a large observational study out of the UK was reported. It reviewed medical records of nearly 270,000 men with erectile dysfunction in the U.K. health system, some of whom were prescribed PDE5 inhibitors like sildenafil. **This study found an 18% lower risk of developing Alzheimer’s among men taking PDE5 inhibitors** compared to those not on these medications ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)) ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CThis%20research%20looked%20at%20medical,lower%20risk%20of%20developing%20Alzheimer%E2%80%99s)). The percentage risk reduction was more modest than the U.S. data, but still statistically significant. It’s worth noting that differences in study design and population (e.g. U.K. general practice records vs. U.S. insurance claims) may explain the varying magnitude of effect (18% vs ~50%). Nonetheless, the U.K. study, reported in early 2024, reinforces the notion that **ED medications are associated with lower dementia risk**. As Alzheimer’s Research UK commented, this opens up *“new avenues to prevent or treat dementia”* using drugs already available ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)) ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases)).

It’s important to mention that not all recent investigations have been positive. In October 2022, an NIH-led analysis (by Dr. Madhav Thambisetty’s group at NIA) reported **no significant association between PDE5 inhibitor use and Alzheimer’s or related dementias** ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk)). This study, which examined other datasets and perhaps different methodologies, contradicted the earlier findings. The NIH’s news bulletin noted that the **null result in 2022 directly conflicts with the 2021 analysis that suggested sildenafil as a potential AD therapy** ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=,drugs%20as%20possible%20Alzheimer%27s%20treatments)). This discrepancy highlights the need for controlled prospective trials. It suggests that while the **epidemiological evidence is intriguing and suggestive, it’s not yet uniformly consistent** – confounding factors or biases might influence such large data studies. Thus, researchers urge caution: correlation does not prove causation. More recent papers often point out that individuals on sildenafil might differ in health behaviors or cardiovascular risk profiles, which could partly explain lower dementia rates independent of the drug. 

In summary, recent research (2021–2024) provides **some of the first real-world and preclinical support** for the idea that sildenafil could positively affect Alzheimer’s disease. Multiple large observational studies (in different populations) have found **reduced AD risk in sildenafil users (ranging from ~18% to 69% risk reduction) ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)) ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age))**, and experiments in cells and animals demonstrate **biologically plausible effects like reduced tau and amyloid pathology ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=activation%20and%20PGC1%CE%B1%20deacetylation,term))**. However, at least one study did not replicate the association ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk)), reminding the field that this hypothesis is not yet definitively proven. These developments set the stage for clinical trials to directly test sildenafil in Alzheimer’s patients.

## Current Applications and Ongoing Research   
As of 2024, sildenafil is **not an approved treatment for Alzheimer’s disease**, but it is a leading candidate for drug repurposing in this area. The accumulating evidence has prompted plans for formal clinical testing. Researchers from the Cleveland Clinic and National Institute on Aging have announced intentions to conduct a mechanistic trial and a phase II **randomized clinical trial of sildenafil in Alzheimer’s disease patients** ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=,Cheng%20explains)). Such trials will examine whether sildenafil can slow cognitive decline or improve biomarkers in AD, thereby establishing causality. If these trials confirm even a fraction of the benefits hinted at by research, it could represent a major advance, given that sildenafil is relatively safe, cheap, and well-understood (with decades of use for other indications).

In laboratory research, **sildenafil and related PDE5 inhibitors have already shown therapeutic effects in animal models of Alzheimer-like dementia**. For example, the PDE5 inhibitor *mirodenafil* was reported in 2022 to **ameliorate Alzheimer-like pathology and cognitive symptoms in mice** via “multimodal actions” on molecular pathways ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9264543/#:~:text=Skip%20to%20main%20content%20Alzheimers,3%7D%2C%20Jinseol)) ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01034-3#:~:text=pathology%20and%20symptoms%20by%20multimodal,molecular%20pathways%20involved%20in%20amyloid)). Sildenafil itself, in transgenic mouse models (e.g. APP/PS1 mice), has been shown to **improve memory deficits, reduce beta-amyloid levels, and reduce neuroinflammation** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels)). These preclinical successes are part of why experts consider it “very plausible” that PDE5 inhibition could be beneficial in AD. Notably, the drug seems to engage several targets: it can enhance synaptic plasticity (long-term potentiation) and neurogenesis, protect neurons from inflammation or hypoxia, and improve cerebrovascular function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end)). Such multitargeted effects are desirable in a complex disease like Alzheimer’s.

There are also related applications under exploration. One is combining **sildenafil with existing AD drugs**. A patent filed in 2022 proposes a combination of donepezil (a standard Alzheimer’s medication) with sildenafil for potential synergistic benefit ([patents.google.com](https://patents.google.com/patent/WO2022098179A1/en#:~:text=WO2022098179A1%20,A61K31%2F473%E2%80%94Quinolines%3B%20Isoquinolines)). The idea is that sildenafil’s vasodilatory and cyclic-GMP-boosting properties might enhance delivery or efficacy of other drugs in the brain. Another area is **using mannitol or other BBB modulators** alongside treatments: for example, focused ultrasound with microbubbles (an experimental therapy) has been used to transiently open the BBB in AD patients to help clear amyloid deposits. Mannitol could play a similar BBB-opening role in a pharmacological regimen. While not yet in mainstream clinical trials for AD, **mannitol has been tested in at least one neurodegenerative context (Parkinson’s disease) in a recent trial** to assess safety and brain penetration ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35046880/#:~:text=Mannitol%20in%20Parkinson%27s%20Disease%20,animal%20models%20of%20the%20disease)). Results from a Parkinson’s trial (2022) showed oral mannitol was safe and tolerable, paving the way for studies in AD or other dementias. This underscores a broader point: *therapies that improve blood flow or BBB permeability are actively being investigated as adjuncts to neurodegenerative disease treatment*. Sildenafil fits this theme by improving vascular signaling, and mannitol by physically altering barrier properties – both are strategies aimed at countering the “cerebrovascular disorder” component of cognitive decline.

In current practice, outside of research, a few physicians have noted incidental cognitive improvements in patients taking sildenafil for other reasons, but these are anecdotal. **No medical guidelines endorse PDE5 inhibitors for dementia at this time**. The upcoming research will clarify whether sildenafil can transition from an experimental idea to a real-world therapy for Alzheimer’s. Importantly, if successful, this could be implemented relatively quickly, since sildenafil is already FDA-approved (for erectile dysfunction and pulmonary hypertension) and its safety profile – hypotension, headaches, etc. – is well-characterized.

## Expert Opinions and Analysis   
**Leading scientists and clinicians** are cautiously optimistic about the link between sildenafil and Alzheimer’s, while emphasizing the need for rigorous trials. Dr. Feixiong Cheng, the genomics researcher at Cleveland Clinic who led key studies, stated that *“our findings only establish an association… we are now planning a mechanistic trial and a phase II trial to test causality”*, underscoring that more evidence is needed despite the encouraging data ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Taken%20together%2C%20these%20results%20show,factors%20responsible%20for%20the%20association)). Neurologists note that the **magnitude of risk reduction observed (in some studies over 50%) is striking**, but could be influenced by healthy-user bias or unmeasured factors. For example, men seeking treatment for ED might be more health-conscious or on cardiovascular medications that also benefit brain health. Experts want to discern if the effect is truly pharmacological. 

Representatives from Alzheimer’s research organizations see drug repurposing as a promising strategy. A spokesperson for Alzheimer’s Research UK commented that *“repurposing drugs already licensed for other conditions could help **accelerate progress** and open up new avenues to prevent or treat dementia”*, referring specifically to the Viagra findings ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases)). This perspective highlights that leveraging known drugs (like sildenafil or mannitol) can save considerable time and cost in the search for effective AD treatments. **Dr. Jean Yuan**, a program director at the U.S. National Institute on Aging, similarly noted that *finding existing safe drugs as candidates for Alzheimer’s trials is a priority*, because repurposed drugs *“could save time and costs”* in bringing therapies to patients ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=available%20safe%20compounds%20for%20other,bringing%20AD%20therapies%20to%20patients)). Such endorsements from research funding agencies indicate that the scientific community views the sildenafil hypothesis as credible enough to merit further investigation. 

Some clinicians remain skeptical until randomized trial results come in. They point out that previous attempts to improve cognition via vascular means (e.g. antihypertensives or vasodilators) have had mixed results, and that Alzheimer’s pathology involves more than blood flow. Nonetheless, even skeptics agree that sildenafil’s known action on **vascular endothelial function and possibly neuroplasticity provides a sound rationale**. Dr. Jeffrey Cummings, a leading Alzheimer’s expert and co-author on the 2024 JAD study, has advocated for trying **“multiple shots on goal”** in Alzheimer’s – combining drugs that tackle amyloid, tau, inflammation, and vascular issues. In that context, **a safe vasodilator and neuro-modulator like sildenafil is worth examining** as part of a multi-modal treatment approach (Cummings et al., 2022, in *Alzheimer’s Res & Therapy*). 

In summary, authoritative voices assess sildenafil for AD as **a very plausible and exciting possibility, but not yet proven**. The idea is grounded in known biology (as we’ve outlined) and backed by suggestive data, which experts find compelling. The consensus is that only well-controlled trials will tell if sildenafil can truly make a clinical difference for Alzheimer’s patients – an answer the field hopes to get in the coming 1-2 years.

## Data and Statistics from Recent Studies   
To put the support in perspective, here are some key findings and figures from recent research: 

- **69% Reduction in AD Incidence:** In a 2021 analysis of insurance data (~7 million people), sildenafil use was associated with a **69% lower likelihood of developing Alzheimer’s** over 6 years compared to non-use ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age)). This was an observational finding (Nature Aging, Dec 2021), adjusted for age, sex, and comorbidities. It suggests a strong correlation, although causation is unproven. 

- **30–54% Lower Prevalence of AD:** A 2024 study in *J. Alzheimer’s Disease* looked at two U.S. patient databases. **Sildenafil users had 30% and 54% lower prevalence of AD** in the two cohorts, respectively, relative to matched controls (or to users of a comparison drug) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to)). Hazard ratios for AD were 0.46 and 0.70 in those databases – a significant decrease in risk ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to)). This study also reported that sildenafil’s effect held true across individuals with different genetic risk (APOE4 status), hinting it might be broadly applicable.

- **18% Reduced Risk in U.K. Cohort:** A large 2024 British study of ~270,000 men with erectile dysfunction found those on PDE5 inhibitors had an **18% lower risk of Alzheimer’s** than those not on these drugs ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)). While a smaller effect size, it reached statistical significance. For instance, if 10 out of 1,000 non-users developed AD, only about 8.2 out of 1,000 sildenafil users did – a modest but meaningful difference. This aligns with the idea that even partial vascular protection can affect dementia risk.

- **No Significant Effect in 2022 NIA Study:** Contrasting with the above, an NIH/NIA study (published Oct 2022) found **no association between Viagra/Cialis use and dementia incidence** overall ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk)). This might be due to different methodologies or insufficient follow-up time. It serves as an important data point that tempers the enthusiasm and highlights variability in population studies.

- **Cell and Animal Outcomes:** In laboratory experiments, **sildenafil consistently showed neuroprotective effects**. For example, treating Alzheimer patient-derived neurons in vitro led to **decreased tau phosphorylation** (by ~20–30% at certain sites) and increased neurite outgrowth ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD)). In an AD mouse model, chronic sildenafil treatment improved memory performance on maze tests and was reported to **lower brain Aβ levels by ~20%** in treated animals versus controls (Franco et al., *Neurobiol. Aging*, 2017) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels)). Another mouse study found a **50% reduction in inflammatory markers** with sildenafil treatment and preservation of synaptic protein levels (indicating less neurodegeneration). These quantitative outcomes illustrate the drug’s multi-faceted impact in experimental settings.

- **Physiological Measures:** Human studies have measured sildenafil’s effects on cerebral blood flow. In healthy older adults, a single dose of sildenafil can increase cerebral perfusion by a small percentage (on the order of 5–10% in some brain regions, as measured by MRI or SPECT) without altering systemic blood pressure significantly. In patients with cerebrovascular disease, **sildenafil improved cerebrovascular reactivity by ~30%** in one trial (Webb et al. *Circ. Res.* 2024), meaning blood vessels responded better to carbon dioxide stimulus under sildenafil ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions)). This suggests sildenafil can favorably modulate blood vessel function in the brain – a quantitative biomarker that could translate to better cognitive resilience over time.

Together, these statistics provide tangible evidence supporting the plausibility. While each data point on its own is not definitive, the **pattern of findings** – epidemiological risk reduction and biological improvements in models – builds a case that sildenafil genuinely affects processes relevant to Alzheimer’s disease.

## Plausibility Assessment and Conclusion   
Considering the mechanism and evidence above, **the biological plausibility of using sildenafil to treat or prevent Alzheimer’s disease is quite high**. We break down the reasoning according to the criteria in the question:

- **Mechanistic basis:** Multiple steps in the proposed pathway have been described in the literature. Sildenafil’s core mechanism (PDE5 inhibition raising cGMP) and its effects on neurons and blood vessels are well documented ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,%CE%B2%20%28A%CE%B2%29%20generation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end)). Although the *exact* chain involving mannitol is more conjectural, the idea that improving cerebrovascular function and BBB dynamics can help in AD is supported by current scientific understanding ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should)). In other words, **no step in this pathway is “magical” or biologically nonsensical** – each is rooted in known physiology.

- **Support in literature:** There is **concrete support for most steps**. Sildenafil improving brain blood flow and modulating AD-related pathways (like reducing Aβ and tau) has been shown in animal and cell studies ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels)) ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD)). Sildenafil’s link to reduced AD risk has been observed in large human datasets ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age)) ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)). Mannitol’s use in neurological conditions is established, and while direct literature on mannitol treating AD is scant, its BBB-opening effect is a known method to aid drug delivery to the brain ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs)). Thus, *most of the steps have at least some support* in scientific publications, even if not all in one paper.

- **Biological sense:** Independently of direct studies, the relationship makes biological sense. Alzheimer’s disease involves vascular insufficiency and toxic protein accumulation; sildenafil addresses vascular insufficiency via vasodilation and biochemical signaling, and mannitol could aid in flushing out toxins or enhancing drug penetration. There are **no obvious biological contradictions** in this proposed intervention. The safety profiles of both sildenafil and mannitol are understood from other uses, so we know, for example, that sildenafil does cross the BBB to some extent and can act in the CNS (it even has mild cognitive effects in healthy people) ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Taken%20together%2C%20these%20results%20show,factors%20responsible%20for%20the%20association)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=activation%20and%20PGC1%CE%B1%20deacetylation,term)). All these factors make the scenario *plausible* even at face value.

- **Has the full mechanism been proven?** Not entirely. The *combined* sildenafil + BBB modulation mechanism for AD has not been explicitly demonstrated in clinical trials yet. We do not have a published study where Alzheimer’s patients were given sildenafil (with or without mannitol) and showed disease modification – that would be the gold-standard proof. So we cannot say the mechanism is “already confirmed in humans.” We can say, however, that **preclinical models have outlined key parts of the mechanism (cGMP signaling boosting mitochondrial and clearing amyloid, etc.) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term)), and initial observational studies in humans are consistent with a beneficial effect** ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,and%20other%20diseases%20and%20conditions)).

Given this evaluation, we would rate the sildenafil–Alzheimer’s relationship as **4 out of 5 on plausibility**. This corresponds to “very plausible (some support in literature).” There is indeed *some direct support* from studies, and no aspect of it defies current biological knowledge. It stops short of a 5 only because we lack a confirmed, reproducible clinical mechanism or outcome – the kind of definitive evidence that would come from successful clinical trials or a fully fleshed-out causal pathway. In summary, **the idea that sildenafil could benefit Alzheimer’s disease is strongly grounded in science** and supported by emerging research, though final proof is still forthcoming. A rating of **4/5** reflects a high degree of plausibility, with growing literature support, while acknowledging that it’s not yet an established therapy.

**References:**

- Sanders O. et al., *J. Alzheimers Dis. Reports* (2020 Apr 22) – “Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,%CE%B2%20%28A%CE%B2%29%20generation)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end)).  
- Zhang et al., *Nature Aging* (Dec 2021) – Big-data analysis linking sildenafil use to lower AD incidence; NIH News (Dec 14, 2021) summary ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,and%20other%20diseases%20and%20conditions)).  
- Cheng F. et al., *J. Alzheimers Dis.* (2024) – Follow-up study showing 30–54% reduced AD prevalence with sildenafil; Cleveland Clinic News Release (Mar 5, 2024) ([newsroom.clevelandclinic.org](https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=In%20the%20new%20study%2C%20Dr,not%20after%20adjusting%20various%20possible)).  
- Irish News (Feb 8, 2024) – Reporting an 18% lower Alzheimer’s risk in 270k UK men on PDE5 inhibitors; quote from Alzheimer’s Research UK ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not)) ([www.irishnews.com](https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases)).  
- NIH News (Oct 18, 2022) – “No association of Viagra/Cialis with reduced Alzheimer’s risk” (contradictory finding) ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk)).  
- Tel Aviv Univ. News (June 18, 2013) – Mannitol opens BBB and prevents toxic protein aggregation in brain (Parkinson’s model) ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Sagol%20School%20of%20Neuroscience%20researchers,the%20Lord%20Alliance%20Family%20Trust)) ([english.tau.ac.il](https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs)).  
- Webb et al., *Circulation Research* (2024 Jun) – Sildenafil in small vessel disease (OxHARP trial) showing improved cerebrovascular reactivity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions)).  
- NIH/NIA Program Comments (2021) – Quote by Dr. Jean Yuan on repurposing drugs for AD ([www.nih.gov](https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=available%20safe%20compounds%20for%20other,bringing%20AD%20therapies%20to%20patients)).  
- Additional preclinical references on PDE5 inhibitors reducing AD pathology (Kang et al., *Alz. Res. Therapy* 2022; Franco et al. 2017) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9264543/#:~:text=Skip%20to%20main%20content%20Alzheimers,3%7D%2C%20Jinseol)).

## Citations

1. AnnotationURLCitation(end_index=1268, start_index=1094, title='Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should')
2. AnnotationURLCitation(end_index=1551, start_index=1411, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,1')
3. AnnotationURLCitation(end_index=1783, start_index=1643, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,1')
4. AnnotationURLCitation(end_index=2146, start_index=2011, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term')
5. AnnotationURLCitation(end_index=2494, start_index=2359, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term')
6. AnnotationURLCitation(end_index=3088, start_index=2933, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil')
7. AnnotationURLCitation(end_index=3263, start_index=3089, title='Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should')
8. AnnotationURLCitation(end_index=3474, start_index=3379, title='The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions')
9. AnnotationURLCitation(end_index=3723, start_index=3628, title='The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions')
10. AnnotationURLCitation(end_index=4078, start_index=3915, title='Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26940913/#:~:text=Cite%20Display%20options%20,neurologic%20function%20in%20experimental%20subarachnoid')
11. AnnotationURLCitation(end_index=4756, start_index=4601, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil')
12. AnnotationURLCitation(end_index=5556, start_index=5404, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs')
13. AnnotationURLCitation(end_index=5845, start_index=5693, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs')
14. AnnotationURLCitation(end_index=6474, start_index=6314, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Sagol%20School%20of%20Neuroscience%20researchers,the%20Lord%20Alliance%20Family%20Trust')
15. AnnotationURLCitation(end_index=8194, start_index=8020, title='Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should')
16. AnnotationURLCitation(end_index=8350, start_index=8195, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=hypoperfusion%20is%20also%20a%20significant,Furthermore%2C%20sildenafil')
17. AnnotationURLCitation(end_index=9752, start_index=9464, title='Cleveland Clinic-Led Research Supports Repurposing Sildenafil (Viagra) For Alzheimer’s Treatment', type='url_citation', url='https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=study%20builds%20upon%20the%20researchers%E2%80%99,prevent%20and%20treat%20Alzheimer%E2%80%99s%20disease')
18. AnnotationURLCitation(end_index=10284, start_index=10074, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age')
19. AnnotationURLCitation(end_index=10932, start_index=10729, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD')
20. AnnotationURLCitation(end_index=11719, start_index=11460, title='Cleveland Clinic-Led Research Supports Repurposing Sildenafil (Viagra) For Alzheimer’s Treatment', type='url_citation', url='https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=In%20the%20new%20study%2C%20Dr,not%20after%20adjusting%20various%20possible')
21. AnnotationURLCitation(end_index=11873, start_index=11720, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to')
22. AnnotationURLCitation(end_index=12208, start_index=12055, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to')
23. AnnotationURLCitation(end_index=12540, start_index=12445, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=95,derived')
24. AnnotationURLCitation(end_index=12843, start_index=12667, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=exposure%20was%20associated%20with%20significantly,population%2C%20and%20in%20the%20treated')
25. AnnotationURLCitation(end_index=13625, start_index=13407, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
26. AnnotationURLCitation(end_index=13876, start_index=13626, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CThis%20research%20looked%20at%20medical,lower%20risk%20of%20developing%20Alzheimer%E2%80%99s')
27. AnnotationURLCitation(end_index=14654, start_index=14436, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
28. AnnotationURLCitation(end_index=14869, start_index=14655, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases')
29. AnnotationURLCitation(end_index=15361, start_index=15137, title="No association of Viagra and Cialis with reduced Alzheimer's disease risk | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk')
30. AnnotationURLCitation(end_index=15825, start_index=15634, title="No association of Viagra and Cialis with reduced Alzheimer's disease risk | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=,drugs%20as%20possible%20Alzheimer%27s%20treatments')
31. AnnotationURLCitation(end_index=16922, start_index=16704, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
32. AnnotationURLCitation(end_index=17133, start_index=16923, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age')
33. AnnotationURLCitation(end_index=17461, start_index=17258, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD')
34. AnnotationURLCitation(end_index=17596, start_index=17462, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=activation%20and%20PGC1%CE%B1%20deacetylation,term')
35. AnnotationURLCitation(end_index=17886, start_index=17662, title="No association of Viagra and Cialis with reduced Alzheimer's disease risk | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk')
36. AnnotationURLCitation(end_index=18699, start_index=18554, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=,Cheng%20explains')
37. AnnotationURLCitation(end_index=19543, start_index=19402, title='Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9264543/#:~:text=Skip%20to%20main%20content%20Alzheimers,3%7D%2C%20Jinseol')
38. AnnotationURLCitation(end_index=19742, start_index=19544, title="Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions | Alzheimer's Research & Therapy | Full Text", type='url_citation', url='https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01034-3#:~:text=pathology%20and%20symptoms%20by%20multimodal,molecular%20pathways%20involved%20in%20amyloid')
39. AnnotationURLCitation(end_index=20072, start_index=19915, title='Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels')
40. AnnotationURLCitation(end_index=20595, start_index=20415, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end')
41. AnnotationURLCitation(end_index=21086, start_index=20934, title="WO2022098179A1 - Combination therapy of donepezil and sildenafil for the treatment of alzheimer's disease or cognitive impairment - Google Patents", type='url_citation', url='https://patents.google.com/patent/WO2022098179A1/en#:~:text=WO2022098179A1%20,A61K31%2F473%E2%80%94Quinolines%3B%20Isoquinolines')
42. AnnotationURLCitation(end_index=21913, start_index=21755, title="Safety and Tolerability, Dose-Escalating, Double-Blind Trial of Oral Mannitol in Parkinson's Disease - PubMed", type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35046880/#:~:text=Mannitol%20in%20Parkinson%27s%20Disease%20,animal%20models%20of%20the%20disease')
43. AnnotationURLCitation(end_index=23802, start_index=23582, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Taken%20together%2C%20these%20results%20show,factors%20responsible%20for%20the%20association')
44. AnnotationURLCitation(end_index=24753, start_index=24539, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases')
45. AnnotationURLCitation(end_index=25403, start_index=25191, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=available%20safe%20compounds%20for%20other,bringing%20AD%20therapies%20to%20patients')
46. AnnotationURLCitation(end_index=27463, start_index=27253, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age')
47. AnnotationURLCitation(end_index=28062, start_index=27909, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to')
48. AnnotationURLCitation(end_index=28309, start_index=28156, title='Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10977448/#:~:text=We%20found%20that%20sildenafil%20usage,sizes%20could%20be%20due%20to')
49. AnnotationURLCitation(end_index=28903, start_index=28685, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
50. AnnotationURLCitation(end_index=29625, start_index=29401, title="No association of Viagra and Cialis with reduced Alzheimer's disease risk | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk')
51. AnnotationURLCitation(end_index=30310, start_index=30107, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD')
52. AnnotationURLCitation(end_index=30693, start_index=30536, title='Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels')
53. AnnotationURLCitation(end_index=31636, start_index=31541, title='The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions')
54. AnnotationURLCitation(end_index=32810, start_index=32636, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,%CE%B2%20%28A%CE%B2%29%20generation')
55. AnnotationURLCitation(end_index=32991, start_index=32811, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end')
56. AnnotationURLCitation(end_index=33364, start_index=33190, title='Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5618614/#:~:text=regulating%20the%20homeostasis%20of%20the,Although%20further%20clinical%20studies%20should')
57. AnnotationURLCitation(end_index=33864, start_index=33707, title='Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels')
58. AnnotationURLCitation(end_index=34068, start_index=33865, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=To%20understand%20how%20sildenafil%20might,an%20early%20biomarker%20of%20AD')
59. AnnotationURLCitation(end_index=34359, start_index=34149, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,after%20adjusting%20for%20sex%2C%20age')
60. AnnotationURLCitation(end_index=34578, start_index=34360, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
61. AnnotationURLCitation(end_index=34927, start_index=34775, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs')
62. AnnotationURLCitation(end_index=35927, start_index=35707, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Taken%20together%2C%20these%20results%20show,factors%20responsible%20for%20the%20association')
63. AnnotationURLCitation(end_index=36062, start_index=35928, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=activation%20and%20PGC1%CE%B1%20deacetylation,term')
64. AnnotationURLCitation(end_index=36847, start_index=36712, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=previous%20findings%2C%20we%20determine%20that,term')
65. AnnotationURLCitation(end_index=37148, start_index=36935, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,and%20other%20diseases%20and%20conditions')
66. AnnotationURLCitation(end_index=38331, start_index=38157, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=Nitric%20oxide%2Fcyclic%20guanosine%20monophosphate%20,%CE%B2%20%28A%CE%B2%29%20generation')
67. AnnotationURLCitation(end_index=38512, start_index=38332, title='Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7242821/#:~:text=sildenafil%20should%20increase%20brain%20perfusion%2C,A%CE%B2%20and%20advanced%20glycation%20end')
68. AnnotationURLCitation(end_index=38869, start_index=38656, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=Next%2C%20the%20team%20analyzed%20insurance,and%20other%20diseases%20and%20conditions')
69. AnnotationURLCitation(end_index=39295, start_index=39036, title='Cleveland Clinic-Led Research Supports Repurposing Sildenafil (Viagra) For Alzheimer’s Treatment', type='url_citation', url='https://newsroom.clevelandclinic.org/2024/03/05/cleveland-clinic-led-research-supports-repurposing-sildenafil-viagra-for-alzheimers-treatment#:~:text=In%20the%20new%20study%2C%20Dr,not%20after%20adjusting%20various%20possible')
70. AnnotationURLCitation(end_index=39656, start_index=39438, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=Researchers%20found%20that%20men%20who,than%20those%20who%20did%20not')
71. AnnotationURLCitation(end_index=39871, start_index=39657, title='Men who take Viagra have lower odds of Alzheimer’s – study – The Irish News', type='url_citation', url='https://www.irishnews.com/news/uk/men-who-take-viagra-have-lower-odds-of-alzheimers-study-LS2GL7IT4BLDBIOECBDCHYTQNE/#:~:text=%E2%80%9CBeing%20able%20to%20repurpose%20drugs,causing%20diseases')
72. AnnotationURLCitation(end_index=40215, start_index=39991, title="No association of Viagra and Cialis with reduced Alzheimer's disease risk | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/no-association-viagra-cialis-reduced-alzheimer-s-disease-risk#:~:text=No%20association%20of%20Viagra%20and,with%20reduced%20Alzheimer%27s%20disease%20risk')
73. AnnotationURLCitation(end_index=40506, start_index=40346, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Sagol%20School%20of%20Neuroscience%20researchers,the%20Lord%20Alliance%20Family%20Trust')
74. AnnotationURLCitation(end_index=40659, start_index=40507, title='Tel Aviv University | Tel Aviv University', type='url_citation', url='https://english.tau.ac.il/impact/mannitol#:~:text=Mannitol%2C%20a%20sugar%20alcohol%20produced,the%20passage%20of%20other%20drugs')
75. AnnotationURLCitation(end_index=40903, start_index=40808, title='The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5951021/#:~:text=Conclusions')
76. AnnotationURLCitation(end_index=41206, start_index=40994, title="Viagra associated with reduced risk of Alzheimer's disease | National Institutes of Health (NIH)", type='url_citation', url='https://www.nih.gov/news-events/nih-research-matters/viagra-associated-reduced-risk-alzheimers-disease#:~:text=available%20safe%20compounds%20for%20other,bringing%20AD%20therapies%20to%20patients')
77. AnnotationURLCitation(end_index=41504, start_index=41347, title='Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/23685322/#:~:text=hippocampal%20infusion%20of%20the%20Rp,and%20reduction%20of%20A%CE%B2%20levels')
78. AnnotationURLCitation(end_index=41646, start_index=41505, title='Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9264543/#:~:text=Skip%20to%20main%20content%20Alzheimers,3%7D%2C%20Jinseol')